Back to Treatments

Treatment

PCSK9 Inhibitors (e.g., Evolocumab)

1
Conditions
50
Trials
70K
Participants
65%
Average Safety

Condition Evidence

Coronary Artery Disease

50 trials · 70K participants

78% effectiveness · 65% safety
PCSK9 Inhibitors (e.g., Evolocumab) | DFDA